Safety and tolerability of antiepileptic drug treatment in children with epilepsy

Renzo Guerrini, Gaetano Zaccara, Giancarlo La Marca, Anna Rosati

Research output: Contribution to journalArticle

Abstract

The aim of treating epilepsy is to control or at least decrease seizures without producing unacceptable adverse effects that impair quality of life. Antiepileptic drugs (AEDs) have been considered amongst the drugs most frequently associated with fatal suspected adverse drug reactions. Physicians must therefore be as familiar with safety and tolerability data of AEDs as they are with the expected therapeutic effects.AEDs may cause dose-related adverse effects (i.e. drowsiness, fatigue, dizziness, blurry vision and incoordination) that, in most cases, may be obviated by lowering the dosage, reducing the number of drugs or switching to a better tolerated AED. AEDs also have the potential of precipitating idiosyncratic adverse effects (i.e. serious cutaneous, haematological and hepatic events), which are more common in children and usually require withdrawal of the AED. Although occurrence of idiosyncratic adverse effects can only rarely be predicted or prevented, there are known risk factors that can help in identifying patients at high risk. Occurrence of an idiosyncratic event in a close relative, a concomitant autoimmune disease, co-treatment with specific drugs, history of a previous allergic drug reaction, starting treatment with high doses and rapid titration have all been associated with a higher risk of idiosyncratic adverse effects.New AEDs have been developed in the last two decades with the aim of improving the benefit-risk balance of AED therapy. Available evidence suggests that the newer AEDs are no more effective but may be somewhat better tolerated than older molecules.We performed a literature review with the aim of evaluating safety and tolerability of second-and third-generation AEDs in children. A PubMed search was conducted with the purpose of identifying English-language studies published between 1 January 1989 and 1 January 2011 that reported any adverse event having occurred in children with epilepsy in whom second-and third-generation AEDs were administered.

Original languageEnglish
Pages (from-to)519-533
Number of pages15
JournalDrug Safety
Volume35
Issue number7
DOIs
Publication statusPublished - 2012

Fingerprint

Drug therapy
Anticonvulsants
Epilepsy
Safety
Therapeutics
Pharmaceutical Preparations
Drug Substitution
Sleep Stages
Dizziness
Therapeutic Uses
Ataxia
Drug-Related Side Effects and Adverse Reactions
Titration
PubMed
Autoimmune Diseases
Fatigue
Hypersensitivity
Seizures
Language
Quality of Life

Keywords

  • Adverse-drug-reactions
  • Antiepileptic-drugs
  • Carbamazepine
  • Children
  • Epilepsy
  • Eslicarbazepine-acetate
  • Felbamate
  • Gabapentin
  • Lacosamide
  • Lamotrigine
  • Levetiracetam
  • Oxcarbazepine
  • Phenobarbital
  • Phenytoin
  • Pregabalin
  • Primidone
  • Rufinamide
  • Stiripentol
  • Tiagabine
  • Topiramate
  • Vigabatrin
  • Zonisamide

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Toxicology

Cite this

Safety and tolerability of antiepileptic drug treatment in children with epilepsy. / Guerrini, Renzo; Zaccara, Gaetano; La Marca, Giancarlo; Rosati, Anna.

In: Drug Safety, Vol. 35, No. 7, 2012, p. 519-533.

Research output: Contribution to journalArticle

Guerrini, Renzo ; Zaccara, Gaetano ; La Marca, Giancarlo ; Rosati, Anna. / Safety and tolerability of antiepileptic drug treatment in children with epilepsy. In: Drug Safety. 2012 ; Vol. 35, No. 7. pp. 519-533.
@article{40f0728146ff4248b9ad35bac2749590,
title = "Safety and tolerability of antiepileptic drug treatment in children with epilepsy",
abstract = "The aim of treating epilepsy is to control or at least decrease seizures without producing unacceptable adverse effects that impair quality of life. Antiepileptic drugs (AEDs) have been considered amongst the drugs most frequently associated with fatal suspected adverse drug reactions. Physicians must therefore be as familiar with safety and tolerability data of AEDs as they are with the expected therapeutic effects.AEDs may cause dose-related adverse effects (i.e. drowsiness, fatigue, dizziness, blurry vision and incoordination) that, in most cases, may be obviated by lowering the dosage, reducing the number of drugs or switching to a better tolerated AED. AEDs also have the potential of precipitating idiosyncratic adverse effects (i.e. serious cutaneous, haematological and hepatic events), which are more common in children and usually require withdrawal of the AED. Although occurrence of idiosyncratic adverse effects can only rarely be predicted or prevented, there are known risk factors that can help in identifying patients at high risk. Occurrence of an idiosyncratic event in a close relative, a concomitant autoimmune disease, co-treatment with specific drugs, history of a previous allergic drug reaction, starting treatment with high doses and rapid titration have all been associated with a higher risk of idiosyncratic adverse effects.New AEDs have been developed in the last two decades with the aim of improving the benefit-risk balance of AED therapy. Available evidence suggests that the newer AEDs are no more effective but may be somewhat better tolerated than older molecules.We performed a literature review with the aim of evaluating safety and tolerability of second-and third-generation AEDs in children. A PubMed search was conducted with the purpose of identifying English-language studies published between 1 January 1989 and 1 January 2011 that reported any adverse event having occurred in children with epilepsy in whom second-and third-generation AEDs were administered.",
keywords = "Adverse-drug-reactions, Antiepileptic-drugs, Carbamazepine, Children, Epilepsy, Eslicarbazepine-acetate, Felbamate, Gabapentin, Lacosamide, Lamotrigine, Levetiracetam, Oxcarbazepine, Phenobarbital, Phenytoin, Pregabalin, Primidone, Rufinamide, Stiripentol, Tiagabine, Topiramate, Vigabatrin, Zonisamide",
author = "Renzo Guerrini and Gaetano Zaccara and {La Marca}, Giancarlo and Anna Rosati",
year = "2012",
doi = "10.2165/11630700-000000000-00000",
language = "English",
volume = "35",
pages = "519--533",
journal = "Drug Safety",
issn = "0114-5916",
publisher = "Adis International Ltd",
number = "7",

}

TY - JOUR

T1 - Safety and tolerability of antiepileptic drug treatment in children with epilepsy

AU - Guerrini, Renzo

AU - Zaccara, Gaetano

AU - La Marca, Giancarlo

AU - Rosati, Anna

PY - 2012

Y1 - 2012

N2 - The aim of treating epilepsy is to control or at least decrease seizures without producing unacceptable adverse effects that impair quality of life. Antiepileptic drugs (AEDs) have been considered amongst the drugs most frequently associated with fatal suspected adverse drug reactions. Physicians must therefore be as familiar with safety and tolerability data of AEDs as they are with the expected therapeutic effects.AEDs may cause dose-related adverse effects (i.e. drowsiness, fatigue, dizziness, blurry vision and incoordination) that, in most cases, may be obviated by lowering the dosage, reducing the number of drugs or switching to a better tolerated AED. AEDs also have the potential of precipitating idiosyncratic adverse effects (i.e. serious cutaneous, haematological and hepatic events), which are more common in children and usually require withdrawal of the AED. Although occurrence of idiosyncratic adverse effects can only rarely be predicted or prevented, there are known risk factors that can help in identifying patients at high risk. Occurrence of an idiosyncratic event in a close relative, a concomitant autoimmune disease, co-treatment with specific drugs, history of a previous allergic drug reaction, starting treatment with high doses and rapid titration have all been associated with a higher risk of idiosyncratic adverse effects.New AEDs have been developed in the last two decades with the aim of improving the benefit-risk balance of AED therapy. Available evidence suggests that the newer AEDs are no more effective but may be somewhat better tolerated than older molecules.We performed a literature review with the aim of evaluating safety and tolerability of second-and third-generation AEDs in children. A PubMed search was conducted with the purpose of identifying English-language studies published between 1 January 1989 and 1 January 2011 that reported any adverse event having occurred in children with epilepsy in whom second-and third-generation AEDs were administered.

AB - The aim of treating epilepsy is to control or at least decrease seizures without producing unacceptable adverse effects that impair quality of life. Antiepileptic drugs (AEDs) have been considered amongst the drugs most frequently associated with fatal suspected adverse drug reactions. Physicians must therefore be as familiar with safety and tolerability data of AEDs as they are with the expected therapeutic effects.AEDs may cause dose-related adverse effects (i.e. drowsiness, fatigue, dizziness, blurry vision and incoordination) that, in most cases, may be obviated by lowering the dosage, reducing the number of drugs or switching to a better tolerated AED. AEDs also have the potential of precipitating idiosyncratic adverse effects (i.e. serious cutaneous, haematological and hepatic events), which are more common in children and usually require withdrawal of the AED. Although occurrence of idiosyncratic adverse effects can only rarely be predicted or prevented, there are known risk factors that can help in identifying patients at high risk. Occurrence of an idiosyncratic event in a close relative, a concomitant autoimmune disease, co-treatment with specific drugs, history of a previous allergic drug reaction, starting treatment with high doses and rapid titration have all been associated with a higher risk of idiosyncratic adverse effects.New AEDs have been developed in the last two decades with the aim of improving the benefit-risk balance of AED therapy. Available evidence suggests that the newer AEDs are no more effective but may be somewhat better tolerated than older molecules.We performed a literature review with the aim of evaluating safety and tolerability of second-and third-generation AEDs in children. A PubMed search was conducted with the purpose of identifying English-language studies published between 1 January 1989 and 1 January 2011 that reported any adverse event having occurred in children with epilepsy in whom second-and third-generation AEDs were administered.

KW - Adverse-drug-reactions

KW - Antiepileptic-drugs

KW - Carbamazepine

KW - Children

KW - Epilepsy

KW - Eslicarbazepine-acetate

KW - Felbamate

KW - Gabapentin

KW - Lacosamide

KW - Lamotrigine

KW - Levetiracetam

KW - Oxcarbazepine

KW - Phenobarbital

KW - Phenytoin

KW - Pregabalin

KW - Primidone

KW - Rufinamide

KW - Stiripentol

KW - Tiagabine

KW - Topiramate

KW - Vigabatrin

KW - Zonisamide

UR - http://www.scopus.com/inward/record.url?scp=84862582703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862582703&partnerID=8YFLogxK

U2 - 10.2165/11630700-000000000-00000

DO - 10.2165/11630700-000000000-00000

M3 - Article

C2 - 22702637

AN - SCOPUS:84862582703

VL - 35

SP - 519

EP - 533

JO - Drug Safety

JF - Drug Safety

SN - 0114-5916

IS - 7

ER -